<DOC>
	<DOCNO>NCT01983761</DOCNO>
	<brief_summary>The goal clinical research study learn safe feasible transplant patient one two unit cord blood change laboratory give . Only patient leukemia , lymphoma myelodysplastic syndrome allow study . The secondary goal obtain preliminary efficacy outcome . Researchers also want learn use cord blood change help control disease . One cord blood unit change administer . The cord blood unit alter change use sugar find small amount blood cell . It play role tell transplant cell go body . Adding sugar cord blood cell laboratory help cord blood cell find way bone marrow faster . This process call fucosylation . `` Conditioning '' chemo medicine give patient prepare receive cord blood transplant cell . This prevent immune system reject cell . Conditioning start transplant . ATG protein remove immune cell cause damage body . Clofarabine design interfere growth development cancer cell . Fludarabine design interfere DNA cancer cell , may cause cancer cell die . This chemotherapy also design block body 's ability reject donor 's bone marrow cell . Melphalan busulfan design bind DNA cell , may cause cancer cell die . MMF tacrolimus design block donor cell grow spread way could cause graft versus host disease ( GVHD -- condition transplant tissue attack recipient 's body ) . This may help prevent GVHD . Rituximab design attach cancer cell , may cause die . A Phase I study treatment patient ( N=25 ) hematologic malignancy MDS candidate dual-cord UCBT ongoing M.D . Anderson Cancer Center Investigator-initiated IND Application , E.J . Shpall , MD , PI . Since August , 2012 , Preliminary result indicate ASC-101 UCBT well-tolerated ASC-101 related untoward adverse event observe . To date , median time neutrophil engraftment ( N=9 ) 15 day , median time platelet engraftment ( N=9 ) 33 day . The trial remain ongoing .</brief_summary>
	<brief_title>Study ASC-101 Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation</brief_title>
	<detailed_description>Central Venous Catheter Placement : You first central venous catheter ( CVC ) place . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form . The chemotherapy , drug study , cord blood transplant give vein CVC . Blood sample also draw CVC . The CVC remain body 2-5 month . Study Plans : If agree take part study , doctor choose one follow 2 study plan base disease age medical history . Fludarabine/Clofarabine/Busulfan/Rituximab/Total Body Irradiation : If 1 80 year age receive high-dose chemotherapy , doctor agrees , receive fludarabine , clofarabine , busulfan , ATG , total body irradiation , possibly rituximab . If receive study plan medication , blood may draw check level busulfan 1 time 4-day course treatment . No 1 teaspoon take blood draw . Day Treatment - Day0 Admit , IV hydration , rituximab 375 mg/m2 ( B cell malignancy ) - Day1 Fludarabine 10 mg/m2 , clofarabine 30 mg/m2 , busulfan AUC 5,000 - Day2 Fludarabine 10 mg/m2 , clofarabine 30 mg/m2 , busulfan AUC 5,000 - Day3 Fludarabine 10 mg/m2 , clofarabine 30 mg/m2 , busulfan AUC 5,000 - Day4 Fludarabine 10 mg/m2 , clofarabine 30 mg/m2 , busulfan AUC 5,000 , rabbit ATG 1.25 mg/kg - Day5 Low-dose TBI 2 Gy AM , rabbit ATG 1.75 mg/kg - Day6 Rest - Day7 Rest - Day8 Cord blood infusion Fludarabine , Melphalan Day Treatment - Day0 Admit , hydration - Day1 Fludarabine 40 mg/m2 IV - Day2 Fludarabine 40 mg/m2 IV , rabbit ATG 1.25 mg/kg - Day3 Fludarabine 40 mg/m2 IV , rabbit ATG 1.75 mg/kg - Day4 Fludarabine 40 mg/m2 IV Melphalan 140 mg/m2 IV - Day5 Rest - Day6 Cord blood infusion Supportive Drugs : Starting Day -3 , receive mycophenolate mofetil tablet mouth 2 time day . If able take tablet mouth , receive MMF vein 2 hour 2 time day . If GVHD Day 100 cord blood transplant , dose MMF gradually lower . If GVHD , MMF may stop 7 day GVHD control . Starting Day -2 , receive tacrolimus vein continuous ( nonstop ) infusion able take mouth . You take tacrolimus mouth 2 time day 6 month . After , tacrolimus dose may gradually lower GVHD . Your doctor discus . Starting Day 0 , receive filgrastim ( G-CSF ) needle skin 1 time day every day white blood count begin recover . Filgrastim design help cell bone marrow divide , help raise white blood cell count quickly , low fever , decrease risk infection . Study Visits : At 6 week , 3 , 6 , 12 month transplant : - You physical exam . - You check possible reaction transplant study drug , include GVHD . - Blood ( 4 teaspoon ) draw routine test , check CMV antibody , genetic test learn donor 's cell `` take '' . The routine blood test repeat often doctor think need . - If doctor think need , bone marrow aspiration check status disease . You need stay hospital 4 week . After leave hospital , continue outpatient hospital area , mean stay close enough able come back visit 100 day transplant . Length Participation : If study suit agree join , one year transplant . You take study early disease get bad , intolerable side effect occur , cord blood infect transplant , unable follow study direction , doctor think best interest . This investigational study . Fucosylation FDA-approved process . It currently use research purpose . Fludarabine , busulfan , clofarabine , melphalan , mycophenolate mofetil , tacrolimus , rituximab FDA approve commercially available give patient leukemia lymphoma cord blood transplant . Total body irradiation deliver use FDA-approved commercially available method . Up 25 patient enrol study . All enrol M.D . Anderson Cancer Center , Scripps Green Hospital , University Hospitals Case Medical Center , Texas Transplant Institute .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Males female : 1 80 year age 2 . Patients AML , ALL , CML , CLL , MDS , NHL HD : Patients AML : first complete remission ( CR1 ) highrisk relapse ( e.g. , highrisk cytogenetics , molecular mutation [ FLT3 , MEK , MLL , ] and/or persistent minimal residual disease evidence flow cytometry &lt; 20 % blast marrow ) , secondary leukemia prior chemotherapy and/or arise MDS , Langerhan 's cell histiocytosis , second third complete remission ( CR2 CR3 ) Patients ALL : CR1 Philadelphia chromosome translocation 4 ; 11 , hypodiploidy , and/or persistent minimal residual disease flow cytometry ) , secondary leukemia prior chemotherapy , CR2 CR3 Patients CML : second chronic phase failure intolerant tyrosine kinase inhibitor , accelerate phase Patients MDS : IPPS INT1 high fail prior therapy Patients NHL : CR2 CR3 follow response prior therapy , relapse , include relapse follow autologous HSCT Patients HD : CR2 CR3 follow response prior therapy , relapse , include relapse follow autologous HSCT 3 . KPS 80 ECOG &lt; 3 ( age 12 year ) Lansky Play Performance Score &gt; 60 % ( age &lt; 12 year ) . Eligibility pediatric patient determined conjunction Institutional pediatrician . 4 . Laboratory data : ALT/AST &lt; 2.0 time upper limit normal ( ULN ) Total bilirubin &lt; 2.0 time ULN Creatinine &lt; 1.6 mg/dL 5 . Left ventricular ejection fraction ( LVEF ) ≥ 40 % 6 . Pulmonary function test ( PFT ) demonstrate diffusion capacity lung carbon monoxide ( DLCO ) ≥ 50 % predict . For child &lt; 7 year age unable perform PFT , oxygen saturation &gt; 92 % room air pulse oximetry allow . 7 . Patients must 2 UCB unit available , match patient 4 , 5 , 6/6 collect 10 HLA class I ( serological ) II ( molecular ) antigen . Each UCB unit must contain minimum dose 1.5 x107 ( red blood cell deplete ) TNC per kg per cord prethaw . Information HLAC DQ locus collect future analysis . 8 . Have backup cell source identify case engraftment failure . The source autologous , allogeneic ( related unrelated ) . 9 . Negative beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization willing use effective contraceptive measure study 10 . Patient , guardian , ability provide write informed consent 1 . Prior allogeneic transplant 2 . Patients 6/6 HLAmatched sibling donor , 10/10 HLAmatched unrelated donor ( MUD ) , untimely availability 10/10 HLAMUD relative need take patient transplant 3 . Active , uncontrolled infection , decompensated congestive heart failure pulmonary insufficiency require oxygen supplementation 4 . Active central nervous system ( CNS ) disease patient history CNS malignancy 5 . Any medical intervention condition , opinion Principal Investigator , could compromise adherence study requirement 6 . Known positive human immunodeficiency virus ( HIV ) , hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) rapid plasma regain ( RPR ) test syphilis 7 . Pregnant breastfeed 8 . Treatment investigational product within 28 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>